A resource on new developments in psoriasis in recognition of Psoriasis Action Month was the most popular story of the week at Healio Dermatology.
Next, joint guidelines from the American Academy of Dermatology and the National Psoriasis Foundation on ultraviolet light-based therapies for the treatment of psoriasis also garnered the attention of readers. Alan Menter, MD, chief of dermatology at Baylor Scott & White in Dallas, crafted thoughtful commentary on this technology that dates back nearly 100 years.
Read on for the top four dermatology stories this week.
Eight stories to read for Psoriasis Action Month
In recognition of Psoriasis Action Month, Healio Dermatology highlights eight recent articles on developments in research and treatment for psoriasis. Read more.
Joint guidelines explore best practices in NB-UVB therapy for psoriasis
Based on the available literature, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines on ultraviolet light-based therapies for the treatment of psoriasis. Here, Healio Dermatology summarizes the joint findings on the risks and benefits of narrowband ultraviolet light B (NB-UVB) treatment. Read more.
Dupixent shows positive results in children with severe atopic dermatitis
Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial. Read more.
Ingenol mebutate gel 0.027% effective for larger areas of actinic keratosis
Ingenol mebutate gel 0.027% was superior to vehicle treatment for actinic keratosis on the face, scalp and chest with areas 250 cm2. Read more.